{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:31:27Z","timestamp":1771468287580,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s11864-021-00840-5","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T15:04:25Z","timestamp":1616511865000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Novel Therapies in the Treatment of Hodgkin Lymphoma"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8644-6801","authenticated-orcid":false,"given":"Xavier","family":"Andrade-Gonzalez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"issue":"1","key":"840_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians. 2020;70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA: A Cancer Journal for Clinicians."},{"issue":"1","key":"840_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1182\/asheducation-2009.1.491","volume":"2009","author":"R K\u00fcppers","year":"2009","unstructured":"K\u00fcppers R. Molecular biology of Hodgkin lymphoma. Hematology. 2009;2009(1):491\u20136. https:\/\/doi.org\/10.1182\/asheducation-2009.1.491.","journal-title":"Hematology."},{"issue":"5878","key":"840_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/299065a0","volume":"299","author":"U Schwab","year":"1982","unstructured":"Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 1982;299(5878):65\u20137. https:\/\/doi.org\/10.1038\/299065a0.","journal-title":"Nature."},{"issue":"3","key":"840_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/ijc.2910290310","volume":"29","author":"H Stein","year":"1982","unstructured":"Stein H, Uch\u00e1nska-Ziegler B, Gerdes J, Ziegler A, Wernet P. Hodgkin and Sternberg-Reed cells contain antigens specific to late cells of granulopoiesis. Int J Cancer. 1982;29(3):283\u201390. https:\/\/doi.org\/10.1002\/ijc.2910290310.","journal-title":"Int J Cancer."},{"issue":"19","key":"840_CR5","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019\u201332. https:\/\/doi.org\/10.1182\/blood-2011-01-293050.","journal-title":"Blood."},{"issue":"14","key":"840_CR6","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1200\/jco.2010.32.8401","volume":"29","author":"C Steidl","year":"2011","unstructured":"Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. Journal of Clinical Oncology. 2011;29(14):1812\u201326. https:\/\/doi.org\/10.1200\/jco.2010.32.8401.","journal-title":"Journal of Clinical Oncology."},{"issue":"23","key":"840_CR7","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/jco.2016.66.4482","volume":"34","author":"MG Roemer","year":"2016","unstructured":"Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34(23):2690\u20137. https:\/\/doi.org\/10.1200\/jco.2016.66.4482.","journal-title":"J Clin Oncol."},{"issue":"13","key":"840_CR8","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/s1470-2045(13)70501-1","volume":"14","author":"A Younes","year":"2013","unstructured":"Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348\u201356. https:\/\/doi.org\/10.1016\/s1470-2045(13)70501-1.","journal-title":"Lancet Oncol."},{"issue":"11","key":"840_CR9","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","volume":"15","author":"MJ Flynn","year":"2016","unstructured":"Flynn MJ, Zammarchi F, Tyrer PC, Akarca AU, Janghra N, Britten CE, et al. ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies. Mol Cancer Ther. 2016;15(11):2709\u201321. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0233.","journal-title":"Mol Cancer Ther."},{"issue":"4","key":"840_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2014","unstructured":"\u2022 Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine. 2014;372(4):311\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1411087 Phase I trial evaluating efficacy of nivolumab in patients with relapsed Hodgkin lymphoma.","journal-title":"New England Journal of Medicine"},{"issue":"31","key":"840_CR11","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/jco.2016.67.3467","volume":"34","author":"P Armand","year":"2016","unstructured":"\u2022 Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733\u20139. https:\/\/doi.org\/10.1200\/jco.2016.67.3467 Initial phase I trial evaluating efficacy of pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.","journal-title":"J Clin Oncol."},{"issue":"3","key":"840_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1200\/jco.2013.53.1194","volume":"32","author":"GP Canellos","year":"2014","unstructured":"Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT. Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol. 2014;32(3):163\u20138. https:\/\/doi.org\/10.1200\/jco.2013.53.1194.","journal-title":"J Clin Oncol."},{"key":"840_CR13","unstructured":"National Comprehensive Cancer Network. Hodgkin lymphoma (Version 2.2020). 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf. Accessed November 2, 2020."},{"issue":"7","key":"840_CR14","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1182\/blood.2019001272","volume":"134","author":"JS Abramson","year":"2019","unstructured":"\u2022 Abramson JS, Arnason JE, LaCasce AS, Redd R, Barnes JA, Sokol L, et al. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood. 2019;134(7):606\u201313. https:\/\/doi.org\/10.1182\/blood.2019001272 Phase I\/II trial evaluating brentuximab vedotin in addition to doxorubicin, vinblastine, and dacarbazine in patients with early-stage Hodgkin lymphoma.","journal-title":"Blood"},{"issue":"11","key":"840_CR15","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1182\/bloodadvances.2020001871","volume":"4","author":"SI Park","year":"2020","unstructured":"Park SI, Shea TC, Olajide O, Reddy NM, Budde LE, Ghosh N, et al. ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma. Blood Adv. 2020;4(11):2548\u201355. https:\/\/doi.org\/10.1182\/bloodadvances.2020001871.","journal-title":"Blood Adv."},{"issue":"6","key":"840_CR16","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","volume":"6","author":"PJ Brockelmann","year":"2020","unstructured":"Brockelmann PJ, Goergen H, Keller U, Meissner J, Ordemann R, Halbsguth TV, et al. Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL Trial. JAMA Oncol. 2020;6(6):872\u201380. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0750 Randomized phase II trial showing efficacy of nivolumab in addition to standard chemotherapy for patients with early-stage Hodgkin lymphoma.","journal-title":"JAMA Oncol"},{"issue":"4","key":"840_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018;378(4):331\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1708984 Randomized phase III trial comparing BV-AVD to AVBD leading to approval of brentuximab vedotin for patients with Hodgkin lymphoma.","journal-title":"N Engl J Med."},{"issue":"10","key":"840_CR18","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood.2019003127","volume":"135","author":"DJ Straus","year":"2020","unstructured":"Straus DJ, D\u0142ugosz-Danecka M, Alekseev S, Ill\u00e9s \u00c1, Picardi M, Lech-Maranda E, et al. Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood. 2020;135(10):735\u201342. https:\/\/doi.org\/10.1182\/blood.2019003127.","journal-title":"Blood."},{"issue":"23","key":"840_CR19","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/jco.19.00315","volume":"37","author":"R Ramchandren","year":"2019","unstructured":"\u2022 Ramchandren R, Domingo-Dom\u00e8nech E, Rueda A, Trn\u011bn\u00fd M, Feldman TA, Lee HJ, et al. Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 Study. J Clin Oncol. 2019;37(23):1997\u20132007. https:\/\/doi.org\/10.1200\/jco.19.00315 Randomized phase II multicenter trial using nivolumab followed by nivolumab+AVD.","journal-title":"J Clin Oncol."},{"issue":"25","key":"840_CR20","doi-asserted-by":"publisher","first-page":"6005","DOI":"10.1182\/blood-2011-12-396556","volume":"119","author":"SJ Proctor","year":"2012","unstructured":"Proctor SJ, Wilkinson J, Jones G, Watson GC, Lucraft HH, Mainou-Fowler T, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood. 2012;119(25):6005\u201315. https:\/\/doi.org\/10.1182\/blood-2011-12-396556.","journal-title":"Blood."},{"issue":"3","key":"840_CR21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","volume":"119","author":"AM Evens","year":"2012","unstructured":"Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119(3):692\u20135. https:\/\/doi.org\/10.1182\/blood-2011-09-378414.","journal-title":"Blood."},{"issue":"26","key":"840_CR22","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","volume":"126","author":"A Forero-Torres","year":"2015","unstructured":"\u2022 Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126(26):2798\u2013804. https:\/\/doi.org\/10.1182\/blood-2015-06-644336 Phase II trial showing efficacy of brentuximab monotherapy in patients with Hodgkin lymphoma who were ineligible for conventional chemotherapy.","journal-title":"Blood"},{"key":"840_CR23","doi-asserted-by":"publisher","unstructured":"Gibb A, Pirrie SJ, Linton K, Warbey V, Paterson K, Davies AJ, et al. Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). Br J Haematol. 2020. https:\/\/doi.org\/10.1111\/bjh.17073.","DOI":"10.1111\/bjh.17073"},{"issue":"30","key":"840_CR24","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1200\/jco.2018.79.0139","volume":"36","author":"AM Evens","year":"2018","unstructured":"Evens AM, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol. 2018;36(30):3015\u201322. https:\/\/doi.org\/10.1200\/jco.2018.79.0139.","journal-title":"J Clin Oncol."},{"issue":"11","key":"840_CR25","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1016\/s2352-3026(20)30275-1","volume":"7","author":"BD Cheson","year":"2020","unstructured":"Cheson BD, Bartlett NL, LaPlant B, Lee HJ, Advani RJ, Christian B, et al. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2020;7(11):e808\u2013e15. https:\/\/doi.org\/10.1016\/s2352-3026(20)30275-1.","journal-title":"Lancet Haematol."},{"issue":"8852","key":"840_CR26","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-l","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051\u20134. https:\/\/doi.org\/10.1016\/0140-6736(93)92411-l.","journal-title":"Lancet."},{"issue":"2","key":"840_CR27","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1200\/jco.1999.17.2.534","volume":"17","author":"HM Lazarus","year":"1999","unstructured":"Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ, et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 1999;17(2):534\u201345. https:\/\/doi.org\/10.1200\/jco.1999.17.2.534.","journal-title":"J Clin Oncol."},{"issue":"3","key":"840_CR28","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/s1470-2045(15)70013-6","volume":"16","author":"AJ Moskowitz","year":"2015","unstructured":"Moskowitz AJ, Sch\u00f6der H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. The Lancet Oncology. 2015;16(3):284\u201392. https:\/\/doi.org\/10.1016\/s1470-2045(15)70013-6.","journal-title":"The Lancet Oncology."},{"key":"840_CR29","doi-asserted-by":"publisher","unstructured":"Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC Transplant BRaVE study. Haematologica. 2020. https:\/\/doi.org\/10.3324\/haematol.2019.243238.","DOI":"10.3324\/haematol.2019.243238"},{"issue":"3","key":"840_CR30","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/annonc\/mdx791","volume":"29","author":"AF Herrera","year":"2018","unstructured":"Herrera AF, Palmer J, Martin P, Armenian S, Tsai NC, Kennedy N, et al. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2018;29(3):724\u201330. https:\/\/doi.org\/10.1093\/annonc\/mdx791.","journal-title":"Ann Oncol."},{"issue":"11","key":"840_CR31","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","volume":"131","author":"AF Herrera","year":"2018","unstructured":"Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183\u201394. https:\/\/doi.org\/10.1182\/blood-2017-10-811224.","journal-title":"Blood."},{"issue":"Supplement 1","key":"840_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2020-138434","volume":"136","author":"AJ Moskowitz","year":"2020","unstructured":"Moskowitz AJ, Shah G, Sch\u00f6der H, Ganesan N, Hancock H, Davey T, et al. Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. Blood. 2020;136(Supplement 1):17\u20138. https:\/\/doi.org\/10.1182\/blood-2020-138434.","journal-title":"Blood"},{"issue":"1","key":"840_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","volume":"132","author":"AS LaCasce","year":"2018","unstructured":"LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40\u20138. https:\/\/doi.org\/10.1182\/blood-2017-11-815183.","journal-title":"Blood."},{"issue":"9323","key":"840_CR34","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/s0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. The Lancet. 2002;359(9323):2065\u201371. https:\/\/doi.org\/10.1016\/s0140-6736(02)08938-9.","journal-title":"The Lancet."},{"issue":"2","key":"840_CR35","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1365-2141.2009.07727.x","volume":"146","author":"AJ Moskowitz","year":"2009","unstructured":"\u2022\u2022 Moskowitz AJ, Perales MA, Kewalramani T, Yahalom J, Castro-Malaspina H, Zhang Z, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol. 2009;146(2):158\u201363. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07727.x Large phase III trial evaluating post-autologous stem cell transplant consolidation with brentuximab vedotin in patients with high risk of Hodgkin lymphoma.","journal-title":"Br J Haematol."},{"issue":"9980","key":"840_CR36","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/s0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853\u201362. https:\/\/doi.org\/10.1016\/s0140-6736(15)60165-9.","journal-title":"Lancet."},{"issue":"25","key":"840_CR37","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","volume":"132","author":"CH Moskowitz","year":"2018","unstructured":"Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639\u201342. https:\/\/doi.org\/10.1182\/blood-2018-07-861641.","journal-title":"Blood."},{"issue":"Supplement 1","key":"840_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2020-136384","volume":"136","author":"AF Herrera","year":"2020","unstructured":"Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston PB, Mei M, et al. Consolidation with nivolumab and brentuximab vedotin after autologous hematopoietic cell transplantation in patients with high-risk Hodgkin lymphoma. Blood. 2020;136(Supplement 1):19\u201320. https:\/\/doi.org\/10.1182\/blood-2020-136384.","journal-title":"Blood"},{"issue":"19","key":"840_CR39","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/jco.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"\u2022\u2022 Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125\u201332. https:\/\/doi.org\/10.1200\/jco.2016.72.1316 Phase II trial that established the efficacy of pembrolizumab in patients with Hodgkin lymphoma.","journal-title":"J Clin Oncol"},{"issue":"14","key":"840_CR40","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1182\/blood.2019000324","volume":"134","author":"R Chen","year":"2019","unstructured":"Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144\u201353. https:\/\/doi.org\/10.1182\/blood.2019000324.","journal-title":"Blood."},{"issue":"14","key":"840_CR41","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/jco.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428\u201339. https:\/\/doi.org\/10.1200\/jco.2017.76.0793.","journal-title":"J Clin Oncol."},{"issue":"9","key":"840_CR42","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1016\/s2352-3026(20)30221-0","volume":"7","author":"CS Diefenbach","year":"2020","unstructured":"Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial. Lancet Haematol. 2020;7(9):e660\u2013e70. https:\/\/doi.org\/10.1016\/s2352-3026(20)30221-0.","journal-title":"Lancet Haematol."},{"issue":"1","key":"840_CR43","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/s2352-3026(18)30192-3","volume":"6","author":"Y Shi","year":"2019","unstructured":"Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019;6(1):e12\u2013e9. https:\/\/doi.org\/10.1016\/s2352-3026(18)30192-3.","journal-title":"Lancet Haematol."},{"issue":"2","key":"840_CR44","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41375-019-0545-2","volume":"34","author":"Y Song","year":"2020","unstructured":"Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, et al. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia. 2020;34(2):533\u201342. https:\/\/doi.org\/10.1038\/s41375-019-0545-2.","journal-title":"Leukemia."},{"issue":"24","key":"840_CR45","doi-asserted-by":"publisher","first-page":"7363","DOI":"10.1158\/1078-0432.Ccr-19-1680","volume":"25","author":"Y Song","year":"2019","unstructured":"Song Y, Wu J, Chen X, Lin T, Cao J, Liu Y, et al. A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma. Clin Cancer Res. 2019;25(24):7363\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1680.","journal-title":"Clin Cancer Res."},{"issue":"Supplement 1","key":"840_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/blood-2020-137451","volume":"136","author":"AF Herrera","year":"2020","unstructured":"Herrera AF, Carlo-Stella C, Collins GP, Maddocks KJ, Bartlett NL, Savage KJ, et al. Preliminary results of a phase 2 study of camidanlumab tesirine (Cami), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020;136(Supplement 1):21\u20133. https:\/\/doi.org\/10.1182\/blood-2020-137451.","journal-title":"Blood"},{"issue":"1","key":"840_CR47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980.","journal-title":"N Engl J Med."},{"issue":"14","key":"840_CR48","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1914347.","journal-title":"N Engl J Med."},{"issue":"26","key":"840_CR49","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med."},{"issue":"5","key":"840_CR50","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","volume":"23","author":"CM Wang","year":"2017","unstructured":"Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial. Clin Cancer Res. 2017;23(5):1156\u201366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1365.","journal-title":"Clin Cancer Res."},{"key":"840_CR51","doi-asserted-by":"publisher","unstructured":"Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020:Jco2001342. https:\/\/doi.org\/10.1200\/jco.20.01342 Pooled analysis of two phase I\/II trials using antiCD30 CAR-T for patients with relapsed and refractory Hodgkin lymphoma.","DOI":"10.1200\/jco.20.01342"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00840-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-021-00840-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00840-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T21:33:17Z","timestamp":1618954397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-021-00840-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["840"],"URL":"https:\/\/doi.org\/10.1007\/s11864-021-00840-5","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"assertion":[{"value":"18 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Dr. Andrade-Gonzalez declares that he has no conflict of interest. Dr Ansell receives research funding (to his institution) from the Bristol Myers Squibb, Seattle Genetics, Takeda, Regeneron, ADC Therapeutics, Affimed, Trillium, and AI Therapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"42"}}